Nu Skin Enterprises, Inc. (NASDAQ:NUS) director Edwina D. Woodbury conducted notable share transactions on June 1, 2026. The activity included the divestiture of a specified amount of company stock, alongside an acquisition of additional shares.
Specifically, Ms. Woodbury sold 7,203 shares of Class A Common Stock at a price point of $5.70 per share. This sale was executed under the terms of a Rule 10b5-1 trading plan, which had been formally adopted on February 19, 2026. In a separate action on the same date, Ms. Woodbury acquired an additional holding of 26,643 shares of Class A Common Stock, at a price listed as $0.00 per share.
These combined transactions resulted in Ms. Woodbury's direct ownership of 62,433 shares of Nu Skin Enterprises Class A Common Stock.
The timing of these insider movements occurs against a backdrop of fluctuating market conditions for Nu Skin. The company’s stock was reported trading near its 52-week low of $5.52, with the current price noted at $5.28.
Further analysis available through InvestingPro suggests that based on its Fair Value assessment, Nu Skin may be considered undervalued, placing it among stocks identified as being highly undervalued. The platform also offers 17 additional tips for NUS investors seeking deeper insights into the company’s future potential.
Beyond the insider activity and current valuation metrics, recent corporate performance data adds context to the stock's movement. Nu Skin Enterprises released its first-quarter earnings report for 2026. These results indicated a challenging period for the firm, as key financial figures missed analyst projections.
The company reported adjusted earnings per share of $0.14. This figure was substantially lower than the $0.27 that had been forecasted by analysts. Furthermore, revenue also underperformed expectations, reaching $320.6 million when analysts had anticipated a total closer to $356.8 million.
These financial developments have drawn attention from various analyst firms. While specific mentions of upgrades or downgrades were not provided in the recent analysis, investors are keenly focused on these reported earnings and revenue numbers as critical indicators for assessing the company’s overall financial health. The situation underscores the importance of continuously monitoring both quarterly financial results and operational metrics when making investment decisions.
The market data presented shows Nu Skin trading at $5.28, which is noted to be down 0.32 (-5.71%) for the day, but also up 0.02 (+0.38%) after hours, suggesting varied intraday and post-market movement.